Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLID: Risedronate in Colles' Fracture
NCT00460733Phase 4Completed
- Sponsor
- Sanofi
- Start
- Mar 2007
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of risedronate in Colles fracture and postmenopausal osteoporosis (2 arms), sponsored by Sanofi. Primary endpoints: Body mineral density of the 33% radius region at 90 days and Body mineral density of the UD radius region at 90 days. Started Mar 2007; status: completed.
02
Drugs
risedronate
03
Conditions
Colles fracturepostmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00460733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00460733.